CVTX CV Therapeutics (MM)

-Data also presented today at European Society of Cardiology Congress 2007-- PALO ALTO, Calif., Sept. 5 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (NASDAQ:CVTX) announced today that data published in Circulation and presented at the European Society of Cardiology Congress 2007 in Vienna, Austria shows that Ranexa(R) (ranolazine extended-release tablets) reduced both ventricular and atrial arrhythmias in patients receiving Ranexa compared to placebo in the MERLIN TIMI-36 study. Patients receiving Ranexa had a 37 percent reduction in their relative risk of ventricular tachycardia lasting eight beats or more (p